Media stories about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.729039976209 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Most Active Stock: Teva Pharmaceutical Industries Limited (TEVA) (badhub.net)
- Teva Pharmaceutical Industries Limited (TEVA) Receives “Outperform” Rating from Oppenheimer Holdings, Inc (ismboard.com)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA) Plans Quarterly Dividend of $0.09 (expressnewsline.com)
- Teva Pharmaceutical Industries Limited (TEVA) Stake Reduced by Barry Investment Advisors LLC (vothemes.com)
- A Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley Downgrades – Benzinga (benzinga.com)
Teva Pharmaceutical Industries Limited (TEVA) opened at 17.50 on Thursday. The stock’s 50 day moving average price is $31.60 and its 200-day moving average price is $32.12. Teva Pharmaceutical Industries Limited has a one year low of $17.47 and a one year high of $55.39. The firm has a market capitalization of $17.78 billion, a price-to-earnings ratio of 224.36 and a beta of 0.46.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.25 earnings per share. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.44 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.94%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.
Several equities analysts have recently issued reports on the stock. Jefferies Group LLC reissued a “hold” rating and set a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Deutsche Bank AG reissued a “buy” rating and set a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Maxim Group reissued a “hold” rating and set a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Friday, August 4th. Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $42.00 to $28.00 in a research note on Friday, August 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Three research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $37.69.
COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/08/10/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-teva-pharmaceutical-industries-limited-teva-share-price.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.